CoChat

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review

Open access
Zhai, Jiaqi, Gu, Xi, Liu, Yang, Hu, Yueting, Jiang, Yi, Zhang, Zhenyong · 2023 · Frontiers in Pharmacology

The DOI matches its Crossref record; 165 of the 167 references it cites were found in a registry or an index.

Abstract

As traditional strategies for cancer treatment, some chemotherapy agents, such as doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor effects by inducing immunogenic cell death (ICD) of tumor cells. ICD induces anti-tumor immunity through release of, or exposure to, damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calreticulin, adenosine triphosphate, and heat shock proteins. This leads to activation of tumor-specific immune responses, which can act in combination with the direct killing functions of chemotherapy drugs on cancer cells to further improve their curative effects. In this review, we highlight the molecular mechanisms underlying ICD, including those of several chemotherapeutic drugs in inducing DAMPs exposed during ICD to activate the immune system, as well as discussing the prospects for application and potential role of ICD in cancer immunotherapy, with the aim of providing valuable inspiration for future development of chemoimmunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2023.1152934

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 The diagram of chemotherapeutic drugs act on tumor cells to induce ICD. The chemotherapeutic drugs stimulate DC to phagocytose antigens and induce DC to mature through the release of a large number of damps. The effect of DC on T cells includes two aspects: DC directly acts on CTL; DC acts on CTL again by secreting IL-6, IL-1β, IFN-γ and TNF-α. The adaptive immune response is subsequently activated and the anti-tumor effect of chemotherapy drugs are enhanced.
FIGURE 1 The diagram of chemotherapeutic drugs act on tumor cells to induce ICD. The chemotherapeutic drugs stimulate DC to phagocytose antigens and induce DC to mature through the release of a large number of damps. The effect of DC on T cells includes two aspects: DC directly acts on CTL; DC acts on CTL again by secreting IL-6, IL-1β, IFN-γ and TNF-α. The adaptive immune response is subsequently activated and the anti-tumor effect of chemotherapy drugs are enhanced.CC BY · PubMed Central
FIGURE 2 The diagram of Anthracyclines and OXA to induce ICD. Anthracyclines and OXA cause phosphorylation of EIF2A in dying tumor cells, and induce CRT translocation in the early stage of apoptosis, ATP secretion, HSP70 release in the middle stage of apoptosis and HMGB1 release in the late stage of apoptosis. CRT is combined with CD91, ATP is combined with P2x7, and HMGB1 is combined with TLR4. In addition, ANXA1 on the surface of tumor cells and FPR1 on the surface of DC are stably combined with the forming cells to promote the maturation of DC, and DC presents antigens to T cells, further killing tumor cells.
FIGURE 2 The diagram of Anthracyclines and OXA to induce ICD. Anthracyclines and OXA cause phosphorylation of EIF2A in dying tumor cells, and induce CRT translocation in the early stage of apoptosis, ATP secretion, HSP70 release in the middle stage of apoptosis and HMGB1 release in the late stage of apoptosis. CRT is combined with CD91, ATP is combined with P2x7, and HMGB1 is combined with TLR4. In addition, ANXA1 on the surface of tumor cells and FPR1 on the surface of DC are stably combined with the forming cells to promote the maturation of DC, and DC presents antigens to T cells, further killing tumor cells.CC BY · PubMed Central
FIGURE 3 The diagram of BTZ to induce ICD. BTZ can significantly induce the expression of HSP90 on the cell surface and mediate the maturation of DC. BTZ triggers ICD by activating cGAS/STING pathway and producing type I IFN.
FIGURE 3 The diagram of BTZ to induce ICD. BTZ can significantly induce the expression of HSP90 on the cell surface and mediate the maturation of DC. BTZ triggers ICD by activating cGAS/STING pathway and producing type I IFN.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 165 references

Cited by

Items 101–144 of 144

Metadata

Authors
Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z.
Affiliations
Sheng Jing Hospital (CN)
Corresponding author
Zhang, Zhenyong
Venue
Frontiers in Pharmacology
Published
2023-04-21
Volume
14
Pages
1152934-1152934
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4366690216
Cited by
131
References
167
Citations by year
2026: 36 · 2025: 51 · 2024: 38 · 2023: 6
FWCI
3.64
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Natural Science Foundation of Liaoning Province
  • National Natural Science Foundation of China
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
immunogenic cell death, targeted therapy, HMGB1, calreticulin, ATP, heat shock proteins, tumor immunology, chemoimmunotherapy, doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, paclitaxel, antitumor immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.